Baird Financial Group Inc. Sells 13,125 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Baird Financial Group Inc. reduced its stake in IQVIA Holdings by 21.5%, selling 13,125 shares, bringing their total holdings to 47,898 shares valued at approximately $8.4 million.
• IQVIA reported $2.81 earnings per share for the last quarter, surpassing analysts' expectations, and had a 5.3% year-over-year revenue increase.
• Hedge funds and institutional investors own 89.62% of IQVIA's stock, with various firms significantly increasing their stakes in the company in recent months.

Baird Financial Group Inc. reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 21.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 47,898 shares of the medical research company's stock after selling 13,125 shares during the quarter. Baird Financial Group Inc.'s holdings in IQVIA were worth $8,444,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. American National Bank & Trust acquired a new position in shares of IQVIA in the first quarter valued at approximately $26,000. Clal Insurance Enterprises Holdings Ltd boosted its holdings in shares of IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock valued at $28,000 after purchasing an additional 131 shares during the last quarter. Golden State Wealth Management LLC grew its stake in shares of IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after buying an additional 130 shares in the last quarter. AllSquare Wealth Management LLC purchased a new position in shares of IQVIA during the 1st quarter valued at approximately $33,000. Finally, ST Germain D J Co. Inc. grew its stake in IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after buying an additional 76 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on IQV. Redburn Partners set a $214.00 target price on shares of IQVIA in a research report on Wednesday, September 3rd. JPMorgan Chase & Co. lowered their target price on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research note on Monday, May 19th. Evercore ISI upped their price target on IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a research report on Wednesday, July 9th. Robert W. Baird upped their price objective on shares of IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a research note on Wednesday, July 23rd. Finally, Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, IQVIA presently has an average rating of "Moderate Buy" and an average target price of $229.86.

IQVIA Stock Down 0.3%

Shares of NYSE IQV traded down $0.65 during midday trading on Monday, hitting $187.03. 846,675 shares of the company's stock were exchanged, compared to its average volume of 1,917,812. The company has a market cap of $31.80 billion, a PE ratio of 27.07, a P/E/G ratio of 2.06 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The firm's fifty day simple moving average is $179.88 and its 200-day simple moving average is $167.23. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $248.03.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business had revenue of $4.02 billion for the quarter, compared to the consensus estimate of $3.96 billion. During the same period in the prior year, the business earned $2.64 earnings per share. The business's revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insider Activity

In other news, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares in the company, valued at $557,352.30. This trade represents a 15.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the transaction, the insider owned 27,178 shares of the company's stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.